论文部分内容阅读
目的 分析PTEN基因在前列腺癌中的突变情况。方法 对 80例前列腺癌冰冻组织 ( 60例来自前列腺癌原发部位 ,2 0例来自盆腔淋巴结转移灶 )中PTEN基因进行聚合酶链反应 -单链构象多态性分析(PCR -SSCP) ,检测PTEN基因突变。结果 共有 32例发生PTEN基因突变 ,突变发生率为 4 0 % ( 32 / 80 )。来自前列腺癌原发部位的 60例标本中有 18例发生PTEN基因突变 ,突变发生率为 30 % ( 18/ 60 ) ;来自盆腔淋巴结转移灶的 2 0例标本中共有 14例发生PTEN基因突变 ,突变发生率为 70 % ( 14/ 2 0 )。后者PTEN基因突变发生率显著高于前者 ( χ2 =10 ,P <0 .0 0 5)。结论 PTEN基因突变在前列腺癌发生、发展、转移中起重要作用。PTEN基因可作为完善前列腺癌诊断的指标及前列腺癌联合基因治疗方案中的目的基因
Objective To analyze the mutation of PTEN gene in prostate cancer. Methods Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis of PTEN gene in 80 cases of prostate cancer frozen tissue (60 cases of primary prostate cancer and 20 cases of pelvic lymph node metastasis) PTEN gene mutation. Results A total of 32 cases of PTEN gene mutation occurred, the mutation rate was 40% (32/80). PTEN gene mutations were found in 18 of 60 specimens from the primary site of prostate cancer, with a mutation rate of 30% (18/60). Of the 20 specimens from pelvic lymph node metastases, a total of 14 PTEN mutations occurred, The mutation rate was 70% (14/200). The latter PTEN gene mutation was significantly higher than the former (χ2 = 10, P <0.05). Conclusion PTEN gene mutation plays an important role in the occurrence, development and metastasis of prostate cancer. PTEN gene can be used as a perfect indicator of diagnosis of prostate cancer and prostate cancer gene therapy in combination gene